Our Group organises 3000+ Global Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ 黑料网 Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.
黑料网 Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers
Micheal Ugrumov
ScientificTracks Abstracts: J Alzheimers Dis Parkinsonism
DOI:
Parkinson’s disease (PD) is characterized by a long development at preclinical (asymptomatic) stage and the first appearance of
motor dysfunctions at a loss of most dopaminergic (DA-ergic) neurons, nigral cell bodies and striatal axons, and a depletion
of 60-70% DA in the striatum. The goal of this study was to search mechanisms of neuroplasticity serving to prevent motor
dysfunctions at presymptomatic stage and the triggers of a transition to symptomatic stage evaluating DA synthesis (tyrosine
hydroxylase (TH) mRNA, protein, activity), release (microdialysis in vivo, slices), uptake (slices), degradation (MAO mRNA,
activity) at original models. At presymptomatic stage motor dysfunctions were prevented due to plasticity of survived DA-ergic
neurons that was manifested by enhanced TH activity, increased spontaneous and stimulated release of DA, and decreased MAO
B activity. Noteworthy, striatal DA was synthesized not only in DA-ergic axons but also in non-dopaminergic neurons containing
individual enzymes, TH or aromatic L-amino acid decarboxylase, in cooperation. At symptomatic stage, despite maintaining of
DA synthesis in DA-ergic neurons at the control level and an increase of DA synthesis in monoenzymatic neurons, intercellular
level of DA dropped up followed by an appearance of motor disorders. Major triggers of motor dysfunctions appeared to be
a decrease of spontaneous and stimulated release of striatal DA and an increase of MAO A activity. PD models of preclinical
and early clinical stages, specified in this study are suitable for development of preventive pharmacotherapy serving to improve
compensatory processes and inhibit triggers of motor dysfunctions.
Michael Ugrumov, academician of Russian Academy of Sciences has completed his MD at Institute of Evolutionary Physiology & Biochemistry (Leningrad), PhD at
Institute of Developmental Biology, Professorship at University Medical School (Moscow). Head of Laboratory of Neural and Neuroendocrine Regulations at Institute of
Developmental Biology RAS, Vice-President of Russian Physiological Society. Member of European Academy of Science and Arts, Serbian Academy of Science and Arts,
French National Academy of Pharmacy. He has published more than 200 papers in peer reviewed journals and served as an editorial board member of 8 International
and Russian journals.
Make the best use of Scientific Research and information from our 700 + peer reviewed, 黑料网 Journals